Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

181. The Utility of Positron Emission Tomography in Epilepsy

The Utility of Positron Emission Tomography in Epilepsy PET Recommendation Report 13 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) The Utility of Positron Emission Tomography in Epilepsy J.G. Burneo, R. Poon, S. Kellett, S. Houle and O.C. Snead Report Date: January 29, 2015 PET Recommendation Report 13 is comprised of 2 sections and is available on the CCO Web site (https://www.cancercare.on.ca) PEBC PET Recommendation Reports page at: https (...) ://www.cancercare.on.ca/ or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca Citation (Vancouver Style): Burneo JG, Poon R, Kellett S, Houle S, Snead OC. The utility of positron emission tomography (PET) in epilepsy. Toronto (ON): Cancer Care Ontario; 2015 Jan 29. Program in Evidence-based Care PET Recommendation Report No.: 13. PET Recommendation Report 13 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) The Utility

2015 Cancer Care Ontario

182. Global burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications

Global burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications Global burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Global burden of epilepsy (...) and the need for coordinated action at the country level to address its health, social and public knowledge implications View/ Open View Statistics Altmetrics Share Citation World Health Assembly, 68 . (‎2015)‎. Global burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications. World Health Organization. Gov't Doc # WHA68.20 Collections Language English Metadata Related items Showing items related by title and MeSH subject

2015 WHO

183. Antidepressants for people with epilepsy and depression. (Full text)

Antidepressants for people with epilepsy and depression. Depressive disorders are the most common psychiatric comorbidity in patients with epilepsy, affecting around one-third, with a significant negative impact on quality of life. There is concern that patients may not be receiving appropriate treatment for their depression because of uncertainty regarding which antidepressant or class works best and the perceived risk of exacerbating seizures. This review aims to address these issues (...) and inform clinical practice and future research.We aimed to review and synthesise evidence from randomised controlled trials of antidepressants and prospective non-randomised studies of antidepressants used for treating depression in patients with epilepsy. The primary objectives were to evaluate the efficacy and safety of antidepressants in treating depressive symptoms and the effect on seizure recurrence.We conducted a search of the following databases: the Cochrane Epilepsy Group Specialised Register

2014 Cochrane PubMed

184. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. (Full text)

Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Epilepsy is defined as the tendency to spontaneous, excessive neuronal discharge manifesting as seizures. It is a common disorder with an incidence of 50 per 100,000 per year and a prevalence of 0.5% to 1% in the developed world (Hauser 1993).Carbamazepine (CBZ) is a widely used antiepileptic drug that is associated with a number of troublesome adverse events including dizziness, double vision (...) on the IR formulation?We searched the Cochrane Epilepsy Group Specialized Register (10 November 2014), Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO) 11 November 2014, and MEDLINE (Ovid, 1946 to 11 November 2014).Randomised controlled trials comparing IR CBZ to CR CBZ in patients commencing monotherapy and patients presently treated with IR CBZ but experiencing unacceptable adverse events.Primary outcome measures include seizure frequency

2014 Cochrane PubMed

185. Perampanel (epilepsy and seizures) ? Benefit assessment according to §35a Social Code Book V

Perampanel (epilepsy and seizures) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Perampanel – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 August 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A14-16 Perampanel – Benefit (...) Vervölgyi ? Siw Waffenschmidt Keywords: perampanel, epilepsies – partial, benefit assessment 2 Due to legal data protection regulations, employees have the right not to be named. Extract of dossier assessment A14-16 Version 1.0 Perampanel – Benefit assessment acc. to §35a Social Code Book V 13 August 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of figures v List of abbreviations vi 2 Benefit assessment 1 2.1 Executive summary

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

186. Women with epilepsy face tough choices over their medication

Women with epilepsy face tough choices over their medication Women with epilepsy face tough choices over their medication - Evidently Cochrane Search and hit Go By October 30, 2014 // In this guest blog consultant neurologist Professor Tony Marson discusses a new Cochrane review on how treatments for epilepsy in pregnancy may affect the unborn child and the dilemma facing young women making decisions about their treatment A published today in the Cochrane Library highlights current evidence (...) about the intelligence of children born to women taking antiepileptic medication. One medication, valproate, is of particular concern as it is associated with a drop in IQ sufficient to impact on educational and employment opportunities. There was no convincing evidence that other commonly used antiepileptic drugs affect offspring’s IQ. As a result, some young women with epilepsy face a very tough choice about which antiepileptic medication to take for their epilepsy. Epilepsy is a common condition

2014 Evidently Cochrane

187. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. (Full text)

Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Accumulating evidence suggests an association between prenatal exposure to antiepileptic drugs (AEDs) and increased risk of both physical anomalies and neurodevelopmental impairment. Neurodevelopmental impairment is characterised by either a specific deficit or a constellation of deficits across cognitive, motor and social skills and can be transient or continuous into adulthood. It is of paramount importance (...) that these potential risks are identified, minimised and communicated clearly to women with epilepsy.To assess the effects of prenatal exposure to commonly prescribed AEDs on neurodevelopmental outcomes in the child and to assess the methodological quality of the evidence.We searched the Cochrane Epilepsy Group Specialized Register (May 2014), Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2014, Issue 4), MEDLINE (via Ovid) (1946 to May 2014), EMBASE (May 2014), Pharmline (May

2014 Cochrane PubMed

188. Epilepsy: new advances. (PubMed)

Epilepsy: new advances. Epilepsy affects 65 million people worldwide and entails a major burden in seizure-related disability, mortality, comorbidities, stigma, and costs. In the past decade, important advances have been made in the understanding of the pathophysiological mechanisms of the disease and factors affecting its prognosis. These advances have translated into new conceptual and operational definitions of epilepsy in addition to revised criteria and terminology for its diagnosis (...) and classification. Although the number of available antiepileptic drugs has increased substantially during the past 20 years, about a third of patients remain resistant to medical treatment. Despite improved effectiveness of surgical procedures, with more than half of operated patients achieving long-term freedom from seizures, epilepsy surgery is still done in a small subset of drug-resistant patients. The lives of most people with epilepsy continue to be adversely affected by gaps in knowledge, diagnosis

2014 Lancet

189. Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes. (Full text)

Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes. Benign Epilepsy with Centro Temporal Spikes (BECTS) is a common epilepsy syndrome with onset in childhood which almost always remits by adolescence. It is characterised by focal seizures associated with motor signs and somatosensory symptoms, at times progressing to become generalised. The characteristic interictal EEG shows normal background activity with centrotemporal (...) spikes which are more prominent in sleep. The prognosis is good though subtle cognitive impairment has been implicated. Antiepileptic drug (AED) treatment is used if seizures are frequent or occurring in the daytime.To evaluate whether or not treatment with AEDs changes the short- or long-term outcome of children with BECTS or both.We searched the following databases: the Cochrane Epilepsy Group Specialized Register (30 April 2013), the Cochrane Central Register of Controlled Trials (CENTRAL

2014 Cochrane PubMed

190. Vagus Nerve Stimulation for Epilepsy

Vagus Nerve Stimulation for Epilepsy Vagus nerve stimulation for epilepsy Vagus nerve stimulation for epilepsy Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vagus nerve stimulation for epilepsy. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' objectives Vagus nerve stimulation (VNS) is a treatment for epilepsy in which electrical (...) pulses are delivered to the cervical portion of the vagus nerve by an implanted pacemaker-like device. The goal of VNS is to reduce the frequency and severity of seizures in patients with seizures that are refractory to medication. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Epilepsy; Vagus Nerve Stimulations Language Published English Country of organisation United States English summary An English language summary is available

2014 Health Technology Assessment (HTA) Database.

191. Epilepsy in pregnancy-a collaborative team effort of obstetricians, neurologists and primary care physicians for a successful outcome

Epilepsy in pregnancy-a collaborative team effort of obstetricians, neurologists and primary care physicians for a successful outcome 112 REPRINTED FROM AusTRAlIAN F AMIly PhysIcIAN VOl. 43, NO. 3, MARch 2014 Neurology Epilepsy in pregnancy A collaborative team effort of obstetricians, neurologists and primary care physicians for a successful outcome Background Epilepsy is the most commonly encountered serious neurological problem in obstetrical practice. The disease and treating medications (...) may have significant impact on contraceptive choice, efficacy and reproduction. Objective This article seeks to inform general practitioners (GPs) about current developments in the field of pregnancy care for women with epilepsy and to foster a collaborative approach in their management. Discussion The care of a pregnant woman with epilepsy needs to start well before pregnancy occurs, while she is still under the care of a GP, especially if she is on antiepileptic medication. GPs are familiar

2014 Clinical Practice Guidelines Portal

192. Felbamate as an add-on therapy for refractory epilepsy. (PubMed)

Felbamate as an add-on therapy for refractory epilepsy. This review is an update of a previously published review in The Cochrane Database of Systematic Reviews (Issue 1, 2011) on 'Felbamate as an add-on therapy for refractory epilepsy'. Epilepsy is a chronic and disabling neurologic disorder, affecting approximately 1% of the population. Up to 30% of people with epilepsy have seizures that are resistant to currently available drugs. Felbamate is one of the second-generation antiepileptic drugs (...) and its effects as an add-on therapy to standard drugs are assessed in this review.To evaluate the efficacy and tolerability of felbamate versus placebo when used as an add-on treatment for people with refractory partial-onset epilepsy.We searched the Cochrane Epilepsy Group Specialized Register (24 July 2013), the Cochrane Central Register of Controlled Trials (CENTRAL 2013, Issue 6), and PubMed (24 July 2013). This search was run for the original review on 20 May 2010. There were no language

2014 Cochrane

193. Deep brain and cortical stimulation for epilepsy. (Full text)

Deep brain and cortical stimulation for epilepsy. Despite optimal medical treatment, including epilepsy surgery, many epilepsy patients have uncontrolled seizures. In the last decades, interest has grown in invasive intracranial neurostimulation as a treatment for these patients. Intracranial stimulation includes both deep brain stimulation (DBS) (stimulation through depth electrodes) and cortical stimulation (subdural electrodes).To assess the efficacy, safety and tolerability of deep brain (...) and cortical stimulation for refractory epilepsy based on randomized controlled trials.We searched PubMed (6 August 2013), the Cochrane Epilepsy Group Specialized Register (31 August 2013), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 7 of 12) and reference lists of retrieved articles. We also contacted device manufacturers and other researchers in the field. No language restrictions were imposed.Randomized controlled trials (RCTs) comparing deep brain

2014 Cochrane PubMed

194. Injury Among Children and Young Adults With Epilepsy (Full text)

Injury Among Children and Young Adults With Epilepsy To investigate whether children and young adults with epilepsy are at a greater risk of fracture, thermal injury, or poisoning than those without.A cohort study was conducted by using the Clinical Practice Research Datalink (1987-2009), a longitudinal database containing primary care records. A total of 11 934 people with epilepsy and 46 598 without, aged between 1 and 24 years at diagnosis, were followed for a median (interquartile range (...) ) of 2.6 (0.8-5.9) years. The risk of fractures (including long bone fractures), thermal injuries, and poisonings (including medicinal and nonmedicinal poisonings) was estimated.Adjusting for age, gender, Strategic Health Authority region, deprivation, and calendar year at study entry (and, for medicinal poisonings, behavior disorder), people with epilepsy had an 18% increase in risk of fracture (hazard ratio [HR] = 1.18; 95% confidence interval [CI], 1.09-1.27), a 23% increase in risk of long bone

2014 EvidenceUpdates PubMed

195. Acupuncture for epilepsy. (PubMed)

Acupuncture for epilepsy. Acupuncture is increasingly used in people with epilepsy. It remains unclear whether existing evidence is rigorous enough to support its use. This is an update of a Cochrane review first published in 2008.To determine the effectiveness and safety of acupuncture in people with epilepsy.We searched the Cochrane Epilepsy Group Specialised Register (June 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2013, Issue 5), MEDLINE (...) Collaboration.We included 17 RCTs with 1538 participants that had a wide age range and were suffering mainly from generalized epilepsy. The duration of treatment varied from 7.5 weeks to 1 year. All included trials had a high risk of bias with short follow-up. Compared with Chinese herbs, needle acupuncture plus Chinese herbs was not effective in achieving at least 50% reduction in seizure frequency (80% in control group versus 90% in intervention group, RR 1.13, 95% CI 0.97 to 1.31, 2 trials; assumed risk 500

2014 Cochrane

196. Sulthiame monotherapy for epilepsy. (Full text)

Sulthiame monotherapy for epilepsy. Epilepsy is a common neurological condition characterised by recurrent seizures. Sulthiame (STM) is widely used as an antiepileptic drug in Europe and Israel. In this review, we present a summary of evidence for the use of STM as monotherapy in epilepsy.To examine the efficacy and side effect profile of STM as monotherapy when compared with placebo or another antiepileptic drug.We searched the Cochrane Epilepsy Group Specialised Register (24 October 2013 (...) of STM in people of any age with epilepsy of any aetiology.Two review authors independently selected trials for inclusion and extracted the relevant data.The following outcomes were assessed: (1) time to treatment failure; (2) time to 12-month remission; (3) proportion seizure free at 12 months; (4) adverse effects; and (5) quality of life scoring. Primary analyses were intention-to-treat when possible. A narrative analysis of the data was presented.Two studies representing 100 participants

2014 Cochrane PubMed

197. Can a ketogenic diet reduce seizures in people with epilepsy?

Can a ketogenic diet reduce seizures in people with epilepsy? Can a ketogenic diet reduce seizures in people with epilepsy? | Evidently Cochrane sharing the latest Cochrane Reviews Search Main menu Post navigation by It’s , when people get doodling to support the work of UK charity . So we thought we’d bring you some Cochrane evidence on whether a ketogenic diet can help people with epilepsy, in doodle form! Doodles by: Sarah & Holly at the UKCC Link: Levy RG, Cooper PN, Giri P, Pulman J

2014 Evidently Cochrane

198. Can a ketogenic diet reduce seizures in people with epilepsy?

Can a ketogenic diet reduce seizures in people with epilepsy? Can a ketogenic diet reduce seizures in people with epilepsy? | Evidently Cochrane sharing the latest Cochrane Reviews Search Main menu Post navigation by It’s , when people get doodling to support the work of UK charity . So we thought we’d bring you some Cochrane evidence on whether a ketogenic diet can help people with epilepsy, in doodle form! Doodles by: Sarah & Holly at the UKCC Link: Levy RG, Cooper PN, Giri P, Pulman J

2014 Evidently Cochrane

199. Can a ketogenic diet reduce seizures in people with epilepsy?

Can a ketogenic diet reduce seizures in people with epilepsy? Can a ketogenic diet reduce seizures in people with epilepsy? - Evidently Cochrane Search and hit Go By March 7, 2014 // It’s , when people get doodling to support the work of UK charity . So we thought we’d bring you some Cochrane evidence on whether a ketogenic diet can help people with epilepsy, in doodle form! Doodles by: Sarah & Holly at the UKCC Editor: since this was published, the review has been updated, with the addition (...) of women’s health and illness in early modern England (MPhil., University of Reading). Can a ketogenic diet reduce seizures in people with epilepsy? by Sarah Chapman is licensed under a 1 Comments on this post It’s very nice picture, useful information with fun / August 14, 2014 Leave a Reply Your email address will not be published. Required fields are marked * Comment Name * E-Mail * Web Sign me up for the newsletter! Latest Posts Leave this field empty if you're human: Sharing health evidence you can

2014 Evidently Cochrane

200. Can a ketogenic diet reduce seizures in people with epilepsy?

Can a ketogenic diet reduce seizures in people with epilepsy? Can a ketogenic diet reduce seizures in people with epilepsy? | Evidently Cochrane sharing the latest Cochrane Reviews Search Main menu Post navigation by It’s , when people get doodling to support the work of UK charity . So we thought we’d bring you some Cochrane evidence on whether a ketogenic diet can help people with epilepsy, in doodle form! Doodles by: Sarah & Holly at the UKCC Link: Levy RG, Cooper PN, Giri P, Pulman J

2014 Evidently Cochrane